Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Sales reflect continued strong growth in oncology and vaccines
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
